Department of Hematology Oncology, University of Pavia & Fondazione, Istituto Di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.
Blood. 2010 Mar 4;115(9):1703-8. doi: 10.1182/blood-2009-09-245837. Epub 2009 Dec 14.
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.
年龄大于 65 岁、血红蛋白水平低于 100 g/L(10 g/dL)、白细胞计数大于 25 x 10(9)/L、外周血blasts 1%或更高,以及全身症状已被证明可预测原发性骨髓纤维化(PMF)诊断时的不良生存。为了研究这些因素在随访期间的获得是否可以预测生存,我们对 525 例定期随访的 PMF 患者进行了研究。当作为多变量 Cox 比例风险模型中的时间依赖性协变量进行分析时,所有 5 个变量在生存分析中均具有显著影响,并包含在 2 个单独的模型中,一个用于所有患者(动态国际预后评分系统[DIPSS]),另一个用于年龄小于 65 岁的患者(年龄调整的 DIPSS)。风险因素根据风险比(HR)赋值得分值。在两个模型中,风险类别均为低、中-1、中-2 和高。通过 HR 估计生存。当风险类别发生变化时,根据 DIPSS,低风险的 HR 为 4.13,中-1 为 4.61,中-2 为 2.54;根据年龄调整的 DIPSS,低风险的 HR 为 3.97,中-1 为 2.84,中-2 为 1.81。这些模型的新颖之处在于可随时对 PMF 患者进行预后评估,这可能对治疗决策有用。